Logo image of IPN.PA

IPSEN (IPN.PA) Stock Price, Quote, News and Overview

EPA:IPN - Euronext Paris - Matif - FR0010259150 - Common Stock - Currency: EUR

110  -2 (-1.79%)

IPN.PA Quote, Performance and Key Statistics

IPSEN

EPA:IPN (3/7/2025, 7:00:00 PM)

110

-2 (-1.79%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High126.7
52 Week Low100.3
Market Cap9.22B
Shares83.81M
Float34.83M
Yearly Dividend1.21
Dividend Yield1.25%
PE15.92
Fwd PE10.66
Earnings (Next)04-16 2025-04-16
IPO12-06 2005-12-06


IPN.PA short term performance overview.The bars show the price performance of IPN.PA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -2 -4 -6 -8

IPN.PA long term performance overview.The bars show the price performance of IPN.PA in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 2 -2 4 6 8

The current stock price of IPN.PA is 110 EUR. In the past month the price decreased by -9.54%. In the past year, price increased by 6.08%.

IPSEN / IPN Daily stock chart

IPN.PA Competitors/Peers

The largest stocks on the EU markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
1LLY.MI ELI LILLY & CO 67 760.43B
LLY.DE ELI LILLY & CO 66.98 760.15B
ZEG.DE ASTRAZENECA PLC 21.82 446.45B
JNJ.DE JOHNSON & JOHNSON 16.81 372.31B
1JNJ.MI JOHNSON & JOHNSON 16.61 367.98B
NOV.DE NOVO NORDISK A/S-B 26.21 355.97B
SNW.DE SANOFI 14.32 275.64B
SAN.PA SANOFI 14.27 274.84B
1SAN.MI SANOFI 14.19 273.18B
6MK.DE MERCK & CO. INC. 12.64 224.82B
1MRKX.MI MERCK & CO. INC. 12.47 221.79B
PFE.DE PFIZER INC 8.69 140.81B

About IPN.PA

Company Profile

IPN logo image Ipsen SA manufactures pharmaceutical products for oncology, neuroscience, and rare diseases. The company is headquartered in Boulogne-Billancourt, Ile-De-France and currently employs 5,325 full-time employees. The company went IPO on 2005-12-06. The firm operates globally through two segments: Specialty Care and Consumer Healthcare. In Specialty Care, the Company is focused on various therapeutic areas, including oncology, neurosciences and rare diseases. Its oncology portfolio includes Somatuline, Decapeptyl, Cabometyx and Onivyde. Its neuroscience portfolio includes Dysport, and in rare diseases key products are NutropinAq and Increlex. Its primary care portfolio includes Smecta, Forlax, Fortrans, Eziclen, and Tanakan. In oncology Ipsen focuses on a number of disease areas, which include neuroendocrine tumors, renal cell carcinoma, hepatocellular carcinoma and pancreatic cancer. In addition, the Company has specialism in neurotoxin research and operates three research and development centers located in France, the United Kingdom and the United States.

Company Info

IPSEN

65 Quai Georges Gorse

Boulogne-Billancourt ILE-DE-FRANCE FR

Employees: 5325

Company Website: https://www.ipsen.com/

Investor Relations: https://www.ipsen.com/investors/

Phone: 33158335000

IPSEN / IPN.PA FAQ

What is the stock price of IPSEN today?

The current stock price of IPN.PA is 110 EUR. The price decreased by -1.79% in the last trading session.


What is the ticker symbol for IPSEN stock?

The exchange symbol of IPSEN is IPN and it is listed on the Euronext Paris - Matif exchange.


On which exchange is IPN.PA stock listed?

IPN.PA stock is listed on the Euronext Paris - Matif exchange.


What is the price forecast or stock price prediction for IPSEN stock?

19 analysts have analysed IPN.PA and the average price target is 127.81 EUR. This implies a price increase of 16.19% is expected in the next year compared to the current price of 110. Check the IPSEN stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is IPSEN worth?

IPSEN (IPN.PA) has a market capitalization of 9.22B EUR. This makes IPN.PA a Mid Cap stock.


How many employees does IPSEN have?

IPSEN (IPN.PA) currently has 5325 employees.


What are the support and resistance levels for IPSEN (IPN.PA) stock?

IPSEN (IPN.PA) has a support level at 109.3 and a resistance level at 111.43. Check the full technical report for a detailed analysis of IPN.PA support and resistance levels.


Is IPSEN (IPN.PA) expected to grow?

The Revenue of IPSEN (IPN.PA) is expected to grow by 7.41% in the next year. Check the estimates tab for more information on the IPN.PA EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy IPSEN (IPN.PA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does IPSEN (IPN.PA) stock pay dividends?

IPSEN (IPN.PA) has a dividend yield of 1.25%. The yearly dividend amount is currently 1.21. Check the full fundamental report for a detailed analysis of IPN.PA dividend history, reliability and sustainability.


When does IPSEN (IPN.PA) report earnings?

IPSEN (IPN.PA) will report earnings on 2025-04-16.


What is the Price/Earnings (PE) ratio of IPSEN (IPN.PA)?

The PE ratio for IPSEN (IPN.PA) is 15.92. This is based on the reported non-GAAP earnings per share of 6.91 and the current share price of 110 EUR. Check the full fundamental report for a full analysis of the valuation metrics for IPN.PA.


IPN.PA Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to IPN.PA. When comparing the yearly performance of all stocks, IPN.PA turns out to be only a medium performer in the overall market: it outperformed 61.26% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

IPN.PA Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to IPN.PA. Both the profitability and the financial health of IPN.PA get a neutral evaluation. Nothing too spectacular is happening here.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

IPN.PA Financial Highlights

Over the last trailing twelve months IPN.PA reported a non-GAAP Earnings per Share(EPS) of 6.91. The EPS decreased by -10.38% compared to the year before.


Industry RankSector Rank
PM (TTM) 10.85%
ROA 8.97%
ROE 13.82%
Debt/Equity 0.09
Chartmill High Growth Momentum
EPS Q2Q%-22.76%
Sales Q2Q%112.35%
EPS 1Y (TTM)-10.38%
Revenue 1Y (TTM)61.09%

IPN.PA Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 67% to IPN.PA. The Buy consensus is the average rating of analysts ratings from 19 analysts.

For the next year, analysts expect an EPS growth of 7.55% and a revenue growth 7.41% for IPN.PA


Ownership
Inst Owners14.93%
Ins Owners0.24%
Short Float %N/A
Short RatioN/A
Analysts
Analysts67.37
Price Target127.81 (16.19%)
EPS Next Y7.55%
Revenue Next Year7.41%